Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 218

1.

Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.

Sims RB.

Vaccine. 2012 Jun 19;30(29):4394-7. doi: 10.1016/j.vaccine.2011.11.058. Epub 2011 Nov 26. Review.

PMID:
22122856
[PubMed - indexed for MEDLINE]
Free Article
2.

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.

PMID:
16752945
[PubMed - indexed for MEDLINE]
3.

An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer.

Wesley JD, Whitmore J, Trager J, Sheikh N.

Hum Vaccin Immunother. 2012 Apr;8(4):520-7. doi: 10.4161/hv.18769. Epub 2012 Feb 28. Review.

PMID:
22370520
[PubMed - indexed for MEDLINE]
4.

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.

Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN.

Cancer Control. 2013 Jan;20(1):7-16. Review.

PMID:
23302902
[PubMed - indexed for MEDLINE]
Free Article
5.

PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.

Cheever MA, Higano CS.

Clin Cancer Res. 2011 Jun 1;17(11):3520-6. doi: 10.1158/1078-0432.CCR-10-3126. Epub 2011 Apr 6.

PMID:
21471425
[PubMed - indexed for MEDLINE]
Free Article
6.

Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.

Thara E, Dorff TB, Pinski JK, Quinn DI.

Maturitas. 2011 Aug;69(4):296-303. doi: 10.1016/j.maturitas.2011.04.012. Epub 2011 May 31. Review.

PMID:
21621934
[PubMed - indexed for MEDLINE]
7.

The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.

Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND.

Eur Urol. 2012 Apr;61(4):639-47. doi: 10.1016/j.eururo.2011.10.027. Epub 2011 Oct 24. Review.

PMID:
22036643
[PubMed - indexed for MEDLINE]
8.

Sipuleucel-T: in metastatic castration-resistant prostate cancer.

Plosker GL.

Drugs. 2011 Jan 1;71(1):101-8. doi: 10.2165/11206840-000000000-00000. Review.

PMID:
21175243
[PubMed - indexed for MEDLINE]
9.

Sipuleucel-T: Prototype for development of anti-tumor vaccines.

Carballido E, Fishman M.

Curr Oncol Rep. 2011 Apr;13(2):112-9. doi: 10.1007/s11912-011-0152-5. Review.

PMID:
21243538
[PubMed - indexed for MEDLINE]
10.

Dendritic cell-based immunotherapy for prostate cancer.

Jähnisch H, Füssel S, Kiessling A, Wehner R, Zastrow S, Bachmann M, Rieber EP, Wirth MP, Schmitz M.

Clin Dev Immunol. 2010;2010:517493. doi: 10.1155/2010/517493. Epub 2010 Nov 4. Review.

PMID:
21076523
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Cancer immunotherapy: sipuleucel-T and beyond.

Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P.

Pharmacotherapy. 2011 Aug;31(8):813-28. doi: 10.1592/phco.31.8.813. Review.

PMID:
21923608
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.

Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlović S.

Prostate. 2004 Aug 1;60(3):197-204.

PMID:
15176049
[PubMed - indexed for MEDLINE]
13.

Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.

Gardner TA, Elzey BD, Hahn NM.

Hum Vaccin Immunother. 2012 Apr;8(4):534-9. doi: 10.4161/hv.19795. Review.

PMID:
22832254
[PubMed - indexed for MEDLINE]
14.

Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.

McKarney I.

Issues Emerg Health Technol. 2007 Sep;(101):1-4.

PMID:
17763575
[PubMed - indexed for MEDLINE]
15.

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.

Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, Whitmore JB, Trager JB, Poehlein CH, Frohlich MW, Urdal DL.

Cancer Immunol Immunother. 2013 Jan;62(1):137-47. doi: 10.1007/s00262-012-1317-2. Epub 2012 Aug 3.

PMID:
22865266
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Sipuleucel-T for the treatment of advanced prostate cancer.

Frohlich MW.

Semin Oncol. 2012 Jun;39(3):245-52. doi: 10.1053/j.seminoncol.2012.02.004. Review.

PMID:
22595047
[PubMed - indexed for MEDLINE]
17.

Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.

Di Lorenzo G, Ferro M, Buonerba C.

BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. Epub 2011 Dec 16. Review.

PMID:
22177289
[PubMed - indexed for MEDLINE]
18.

The evolving role of immunotherapy in prostate cancer.

Gerritsen WR.

Ann Oncol. 2012 Sep;23 Suppl 8:viii22-7. doi: 10.1093/annonc/mds259. Review.

PMID:
22918924
[PubMed - indexed for MEDLINE]
Free Article
19.

Sipuleucel-T (APC8015) for prostate cancer.

So-Rosillo R, Small EJ.

Expert Rev Anticancer Ther. 2006 Sep;6(9):1163-7. Review.

PMID:
17020451
[PubMed - indexed for MEDLINE]
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk